Abivax Shares Continue to Decline as Bearish Bets Intensify
The French biotech company experiences another session in the red, extending a downward trend that has been in place for several weeks. The stock is moving against the slightly positive SBF 120, in a context where bearish bets on the capital continue to rise. The technical setup remains degraded across all horizons.
The stock plunges below its moving averages, losing a quarter of its value in one month
Abivax drops 1.83% to €79.22 during the session, extending a decline of more than 25% over one month and nearly 19% over three months. Nonetheless, the stock still sits on an exceptional one-year performance, with a legacy of an extraordinary annual performance of 1,315% over twelve months, stemming from its 2025 stock market journey. Today's session continues the previous day's downturn (nearly 6% lost), already commented on, and erases the rebound outlined at the beginning of the week. The technical configuration weighs heavily: the price is 9.7% below the MM20 (€87.72), nearly 18% below the MM50 (€96.56), and 17.2% below the MM200 (€95.66). The three moving averages are aligned above the price, signaling a bearish trend established at all scales. The RSI at 39 remains in the low-neutral zone, without a real oversold signal, while the support identified at €63.10 still leaves some margin before being threatened.
Selling pressure intensifies with a cumulative short position more than doubling in a month
According to reviewed statements, six funds together hold 6.77% of the capital sold short, compared to 2.94% thirty days ago, marking a progression of 3.83 points in one month. The pace of accumulation of bearish bets reflects a quickly rising mistrust among institutional investors positioned against the stock, without necessarily prejudging their horizon or motivation. This sequence follows the phase 3 results of obefazimod published in early June, where the two doses tested in ulcerative colitis had met their primary efficacy criterion, before the market focused on certain safety signals from the trial. The biotech, listed both on Euronext Paris and on the Nasdaq via real-time synchronized ADS, remains highly exposed to international flows. The next technical test is at the support level of €63.10, still about 20% away from the current price.
